To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-ve Metastatic Breast Cancer|Germline BRCA1/2 Mutations|Somatic BRCA1/2 Mutations
Interventions: DRUG: Olaparib
Sponsor: AstraZeneca